Contract analysis

I. Executive Summary The purpose of this memorandum is to analyze the Claim Construction Order issued on December 6, 2024 by Chief Judge Richard G. Andrews of the United States District Court for the District of Delaware and to assess its impact on the defense strategy for all three accused PrecisionEdge™ product lines. This analysis draws on the proceedings to date—including Solstice's individual Claim Construction

II. Background A. The Asserted Patents Apex Surgical Innovations, Inc. ("Apex") asserts three patents in this action, all of which relate to surgical trocar technology used in minimally invasive laparoscopic procedures. The named inventor on all three patents is Dr. Raymond Szabo, Vice President of Engineering at Apex. All three patents are assigned to Apex. The patent family to which these three patents belong inclu

III. Summary of the Claim Construction Order A. Overview of the Nine Disputed Terms The Court's December 6, 2024 Order addressed all nine claim terms that the parties identified as disputed. The following table summarizes each disputed term, the patent and claims in which it appears, each party's proposed construction, the Court's adopted construction, and our assessment of which party the construction favors. As the

IV. Impact Analysis by Accused Product Line A. PrecisionEdge™ PE-5000 Series (5 mm Trocar)

1. Non-Infringement Position — '237 Patent (Claims 1, 3, 7, 12) The Claim Construction Order materially strengthens the non-infringement position for the PE-5000 Series as to the '237 Patent. The Court's favorable construction of "locking seal assembly" (Term 1) is the cornerstone of this position. As construed, the term requires "a mechanically actuated seal comprising at least two cooperating components with a posi

2. Non-Infringement Position — '884 Patent (Claims 1, 2, 5, 9, 14) The non-infringement position for the PE-5000 as to the '884 Patent is even stronger. The Court's favorable construction of "retractable blade deployment mechanism" (Term 2) is dispositive for most, if not all, asserted claims. The PE-5000 employs a dual-actuator system in which a separate deployment spring advances the blade to a cutting position and

3. Recommendation. We recommend that Solstice move for summary judgment of non-infringement on the PE-5000 Series as to both the '237 Patent and the '884 Patent. The target filing date should be early April 2025, after the close of expert reports and rebuttal reports, which will allow us to incorporate and rely on Dr. Ostrowski's expert opinions and to address any arguments raised by Dr. Ng in his infringement report

1. Non-Infringement Position — '237 Patent (Claims 1, 3, 7, 12) The PE-12000's non-infringement position as to the '237 Patent is mixed. The Court's favorable construction of "locking seal assembly" (Term 1) provides a basis for argument, but the outcome is less clear-cut than for the PE-5000. The PE-12000 uses a two-component seal, which satisfies the "at least two cooperating components" requirement. However, the P

2. Non-Infringement Position — '884 Patent (Claims 1, 2, 5, 9, 14) The PE-12000's non-infringement position on the '884 Patent is weaker than the PE-5000's but still presents legitimate arguments. The favorable construction of "retractable blade deployment mechanism" (Term 2) requires "a single spring-actuated mechanism that both deploys and retracts the blade." The PE-12000 does use a single spring mechanism for bla

3. Non-Infringement Position — '105 Patent (Claims 1, 4, 8) The PE-12000's non-infringement position on the '105 Patent is mixed and will depend on technical evidence regarding the PE-12000's gas pathway architecture. The favorable construction of "insufflation port in fluid communication with the seal assembly" (Term 4) requires a "direct, dedicated fluid pathway" and excludes configurations where gas flows through

4. Invalidity Strategy for PE-12000–Related Claims Given the weaker non-infringement position for the PE-12000, it is critical to strengthen the invalidity defense for the claims most likely to be asserted against this product. The prior art identified by Kendrick & Lau LLP and detailed in the Invalidity Contentions memorandum dated September 18, 2024 remains robust, particularly for Claims 1 and 2 of the '884 Patent

5. Recommendation. We do not recommend seeking summary judgment on the PE-12000 Series. The factual disputes regarding the rotational cam versus detent distinction, the safety override issue, and the gas flow pathway analysis make summary judgment impractical and risky. A denied motion could signal weakness to the Court and consume valuable resources. Instead, we recommend the following approach for the PE-12000: • F

1. Non-Infringement Position — '884 Patent (Claims 1, 2, 5, 9, 14) The PE-15000's non-infringement position on the '884 Patent is similar to the PE-12000's and faces many of the same challenges. Like the PE-12000, the PE-15000 uses a single spring mechanism for blade deployment and retraction but incorporates a manual safety override. The favorable construction of "retractable blade deployment mechanism" (Term 2) pro

2. Non-Infringement Position — '105 Patent (Claims 1, 4, 8) The PE-15000's non-infringement position on the '105 Patent presents the strongest defense available for this product line. The favorable construction of "insufflation port in fluid communication with the seal assembly" (Term 4) is the centerpiece of this defense. The PE-15000's gas pathway includes a dedicated intermediary pressure-regulation chamber situat

3. Invalidity Strategy for PE-15000–Related Claims The invalidity strategy for the PE-15000 largely parallels the approach for the PE-12000 on the '884 Patent claims. The same prior art references and the same analytical framework apply, as the PE-15000 is accused of infringing the same '884 Patent claims as the PE-12000. For the '105 Patent, the broadened "integrated insufflation valve" construction (Term 8) is a si

4. Recommendation. We do not recommend seeking summary judgment on the PE-15000 Series generally. The factual disputes on the '884 Patent claims are too significant for summary judgment, and a broad motion would likely be denied. However, we should carefully evaluate whether a narrower partial summary judgment motion limited to the '105 Patent claims could succeed based on the favorable Term 4 construction and the PE

V. Impact on Invalidity Defenses A. General Observations The Markman ruling's impact on the invalidity defenses is somewhat paradoxical. Favorable claim constructions that narrow the claims are beneficial for non-infringement but can reduce the universe of invalidating prior art by requiring that the prior art disclose the narrower claim limitations. Conversely, unfavorable broader constructions that expand claim sco

VI. Impact on Damages Exposure A. Revised Damages Framework Apex's damages expert, Hugh Danaher of Keystone Valuation Advisors LLC, has previewed a reasonable royalty damages claim of $31.8 million in his damages contentions, with his full expert report expected to be served on or about February 14, 2025. This figure is based on the full accused product sales base of $74.6 million (2021 through Q3 2024, with projecti

VII. Expert discovery Preparation A. Dr. Miriam Ostrowski — Invalidity / Claim Construction Expert Dr. Ostrowski's opening expert report is due January 27, 2025—forty-seven days from the date of this memorandum. Her report must incorporate the Court's claim constructions into the invalidity analysis. Key areas for her attention include: (a) '237 Patent Anticipation Analysis: Adapt the anticipation analysis to account